340 related articles for article (PubMed ID: 27338360)
41. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
Barthélémy P; Hoch B; Chevreau C; Joly F; Laguerre B; Lokiec F; Duclos B
Crit Rev Oncol Hematol; 2013 Oct; 88(1):42-56. PubMed ID: 23523056
[TBL] [Abstract][Full Text] [Related]
42. mTOR inhibitors in advanced renal cell carcinoma.
Voss MH; Molina AM; Motzer RJ
Hematol Oncol Clin North Am; 2011 Aug; 25(4):835-52. PubMed ID: 21763970
[TBL] [Abstract][Full Text] [Related]
43. mTOR kinase inhibitors as potential cancer therapeutic drugs.
Sun SY
Cancer Lett; 2013 Oct; 340(1):1-8. PubMed ID: 23792225
[TBL] [Abstract][Full Text] [Related]
44. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
Montero JC; Esparís-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocaña A; Pandiella A
Oncogene; 2014 Jan; 33(2):148-56. PubMed ID: 23246963
[TBL] [Abstract][Full Text] [Related]
45. Dissecting the role of mTOR: lessons from mTOR inhibitors.
Dowling RJ; Topisirovic I; Fonseca BD; Sonenberg N
Biochim Biophys Acta; 2010 Mar; 1804(3):433-9. PubMed ID: 20005306
[TBL] [Abstract][Full Text] [Related]
46. Phenotypes associated with inherited and developmental somatic mutations in genes encoding mTOR pathway components.
Saxena A; Sampson JR
Semin Cell Dev Biol; 2014 Dec; 36():140-6. PubMed ID: 25263008
[TBL] [Abstract][Full Text] [Related]
47. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
Danesi R; Boni JP; Ravaud A
Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
[TBL] [Abstract][Full Text] [Related]
48. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
Shuuin T; Karashima H
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
[TBL] [Abstract][Full Text] [Related]
49. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
Weigelt B; Warne PH; Downward J
Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673
[TBL] [Abstract][Full Text] [Related]
50. Synthesis and anticancer activity of novel rapamycin C-28 containing triazole moiety compounds.
Huang Q; Xie L; Chen X; Yu H; Lv Y; Huang X; Ying J; Zheng C; Cheng Y; Huang J
Arch Pharm (Weinheim); 2018 Nov; 351(11):e1800123. PubMed ID: 30357890
[TBL] [Abstract][Full Text] [Related]
51. mTOR pathway inhibition in renal cell carcinoma.
Pinto Marín A; Redondo Sánchez A; Espinosa Arranz E; Zamora Auñón P; Castelo Fernández B; González Barón M
Urol Oncol; 2012; 30(4):356-61. PubMed ID: 20207176
[TBL] [Abstract][Full Text] [Related]
52. mTORC1 inhibitors rapamycin and metformin affect cardiovascular markers differentially in ZDF rats.
Nistala R; Raja A; Pulakat L
Can J Physiol Pharmacol; 2017 Mar; 95(3):281-287. PubMed ID: 28177677
[TBL] [Abstract][Full Text] [Related]
53. Mammalian target of rapamycin complex 2 signaling pathway regulates transient receptor potential cation channel 6 in podocytes.
Ding F; Zhang X; Li X; Zhang Y; Li B; Ding J
PLoS One; 2014; 9(11):e112972. PubMed ID: 25393730
[TBL] [Abstract][Full Text] [Related]
54. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
Smolewski P
Anticancer Drugs; 2006 Jun; 17(5):487-94. PubMed ID: 16702804
[TBL] [Abstract][Full Text] [Related]
55. Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island.
Arriola Apelo SI; Lamming DW
J Gerontol A Biol Sci Med Sci; 2016 Jul; 71(7):841-9. PubMed ID: 27208895
[TBL] [Abstract][Full Text] [Related]
56. Targeting mTOR signaling pathway in ovarian cancer.
Mabuchi S; Hisamatsu T; Kimura T
Curr Med Chem; 2011; 18(19):2960-8. PubMed ID: 21651485
[TBL] [Abstract][Full Text] [Related]
57. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
Le Tourneau C; Faivre S; Serova M; Raymond E
Br J Cancer; 2008 Oct; 99(8):1197-203. PubMed ID: 18797463
[TBL] [Abstract][Full Text] [Related]
58. Everolimus and sirolimus in transplantation-related but different.
Klawitter J; Nashan B; Christians U
Expert Opin Drug Saf; 2015 Jul; 14(7):1055-70. PubMed ID: 25912929
[TBL] [Abstract][Full Text] [Related]
59. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors.
Zaza G; Tomei P; Ria P; Granata S; Boschiero L; Lupo A
Clin Dev Immunol; 2013; 2013():403280. PubMed ID: 24151517
[TBL] [Abstract][Full Text] [Related]
60. Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control.
Herrero-Sánchez MC; Rodríguez-Serrano C; Almeida J; San-Segundo L; Inogés S; Santos-Briz Á; García-Briñón J; SanMiguel JF; Del Cañizo C; Blanco B
Br J Haematol; 2016 Jun; 173(5):754-68. PubMed ID: 26914848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
